奥氮平和利培酮治疗女性精神分裂症的疗效,认知功能,安全性的比较

Comparison between olanzapine and risperidone in treating females with schizophrenia in terms of curative effect,cognitive function,and safety

目的探究奥氮平和利培酮治疗女性精神分裂症的疗效,认知功能和安全性。方法将2022年2月~2023年4月本院收治的94例女性精神分裂症患者随机分为奥氮平组和利培酮组,分别给予奥氮平,利培酮治疗,连续治疗4周。对两组患者治疗前后的阳性和阴性症状量表(Positive and Negative Symptom Scale,PANSS),阳性症状评定量表(Scale for Assessment of Positive Symptoms,SAPS),简明精神病评定量表(Brief Psychiatric Rating Scale,BPRS),简易智力状态检查量表(Mini-Mental State Examination,MMSE)和临床总体印象疗效总评量表病情-严重程度(Clinical Global Impression-Severity of Illness,CGI-SI)评分进行比较,同时比较两组药物不良反应情况。结果治疗后,两组PANSS量表,SAPS量表和BPRS量表各维度评分及总分均低于治疗前,但治疗后组间PANSS,SAPS,BPRS评分比较无明显差异(P>0.05)。治疗后,两组CGI-SI评分均低于治疗前(P<0.05),但两组组间CGI-SI评分比较,差异无统计学意义(P>0.05)。治疗后,两组MMSE量表中定向力,记忆注意和计算维度评分及量表总分均高于治疗前(P<0.05);但治疗后组间各评分比较无明显差异(P>0.05)。安全性评价结果显示,奥氮平组兴奋或激越,血糖升高,恶心呕吐,心动过速,体重增加等的发生率高于利培酮组(P<0.05)。结论奥氮平与利培酮在治疗精神分裂症方面具有相同的疗效,对患者临床症状,认知功能改善程度相当,但利培酮对患者神经系统,心血管系统等的影响较小,安全性相对更高。

Objective To compare olanzapine with risperidone in treating females with schizophrenia in terms of curative effect,cognitive function,and safety.Methods Ninety-four female patients with schizophrenia admitted to the hospital from February 2022 to April 2023 were randomly divided into olanzapine group and risperidone group.They were treated with olanzapine and risperidone,respectively.Both groups received 4 weeks of continuous treatment.Positive And Negative Syndrome Scale(PANSS)scores,Scale for Assessment of Positive Symptoms(SAPS)scores,Brief Psychiatric Rating Scale(BPRS)scores,Mini-Mental State Examination(MMSE)scores and Clinical Global Impression-Severity of Illness(CGI-SI)scores before and after treatment,adverse reactions were compared between the two groups.Results After treatment,the scores for different dimensions in PANSS,SAPS and BPRS,scores,and total scores of both groups were lower than those before treatment,but there was no statistically significant difference between groups(P>0.05).After treatment,the CGI-SI scores of both groups were lower than those before treatment(P<0.05),but there was no statistically significant difference between groups(P>0.05).After treatment,the scores for orientation,memory,attention,and computation in the MMSE,and total scores of both groups were higher than those before treatment(P<0.05),but there was no significant difference between groups(P>0.05).Safety evaluation results showed that the incidence rate of excitement or agitation,elevated blood glucose,nausea and vomiting,tachycardia and weight gain of the olanzapine group were higher than those of the risperidone group(P<0.05).Conclusion Olanzapine and risperidone have similar therapeutic effects on schizophrenia,and are comparable in improving clinical symptoms and cognitive function in the patients.However,risperidone has less influence on the patient's nervous system and cardiovascular system,and is relatively safer.